Drug Trial Radar · NCT05526716
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,080
Actual
Start
Sep 23, 2022
Primary completion
Jun 21, 2023
Study completion Jun 21, 2023
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with Quadrivalent Influenza Vaccine (QIV) compared with V116 administered sequentially with QIV. The primary hypotheses state that immune responses to V116 and to QIV are non-inferior when administered concomitantly as compared with sequential administration as measured by serotype-specific opsonophagocytic activity (OPA) for V116 and hemagglutination inhibition (HAI) geometric mean titers (GMTs) for QIV, at 30 days postvaccination.
Conditions
- Pneumonia, Pneumococcal
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
QIVBiological
Single 0.5 mL IM injection
Matching Placebo for V116Biological
Single 0.5 mL of sterile saline IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Solicited Injection-site Adverse Events (AEs)Time frame: Up to 5 days post-vaccination
- Number of Participants With Solicited Systemic AEsTime frame: Up to 5 days post-vaccination
- Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs)Time frame: Up to ~6 months postvaccination with V116
- Geometric Mean Titer (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) ResponsesTime frame: 30 days after V116 vaccination (Day 30 for concomitant group and Day 59 for sequential group)
- GMT of Influenza Strain-specific Hemagglutination Inhibition (HAI)Time frame: Day 30
Locations
56 sites in 1 country. Site status is shown where the registry gives one.
Central Phoenix Medical Clinic-Synexus Clinical Research US ( Site 0012)
Phoenix, Arizona
Hope Clinical Research, Inc. ( Site 0070)
Canoga Park, California
Paradigm Clinical Research Centers, Inc ( Site 0024)
La Mesa, California
Catalina Research Institute, LLC ( Site 0067)
Montclair, California
WR- PRI, LLC ( Site 0044)
Newport Beach, California
Carbon Health - North Hollywood - NoHo West ( Site 0016)
North Hollywood, California
Valley Clinical Trials, Inc. ( Site 0002)
Northridge, California
Artemis Institute for Clinical Research ( Site 0023)
San Diego, California
WR-MCCR, LLC ( Site 0033)
San Diego, California
California Research Foundation ( Site 0005)
San Diego, California
Diablo Clinical Research, Inc. ( Site 0020)
Walnut Creek, California
Velocity Clinical Research, Hallandale Beach ( Site 0064)
Hallandale, Florida
Indago Research & Health Center, Inc ( Site 0029)
Hialeah, Florida
East Coast Institute for Research, LLC ( Site 0013)
Jacksonville, Florida
Health Awareness ( Site 0034)
Jupiter, Florida
Optimal Research ( Site 0008)
Melbourne, Florida
Suncoast Research Group-Clinical Department ( Site 0062)
Miami, Florida
Suncoast Research Associates ( Site 0041)
Miami, Florida
Alpha Science Research ( Site 0042)
Miami, Florida
Lakes Research ( Site 0063)
Miami Lakes, Florida
Triple O Research Institute, P.A ( Site 0054)
West Palm Beach, Florida
East Coast Institute for Research - Canton ( Site 0004)
Canton, Georgia
Clinical Research Atlanta ( Site 0068)
Stockbridge, Georgia
Synexus Clinical Research US, Inc. ( Site 0072)
Chicago, Illinois
Healthcare Research Network - Chicago ( Site 0014)
Flossmoor, Illinois
Centennial Medical Group ( Site 0035)
Elkridge, Maryland
Healthcare Research Network - St. Louis ( Site 0011)
St Louis, Missouri
Radiant Research ( Site 0073)
St Louis, Missouri
Alivation Research-Primary Care ( Site 0066)
Lincoln, Nebraska
WR-CRCN, LLC ( Site 0018)
Las Vegas, Nevada
Axces Research ( Site 0037)
Santa Fe, New Mexico
Smith Allergy and Asthma Specialists-Certified Research Associates ( Site 0019)
Cortland, New York
Synexus Clinical Research US, Inc - New York ( Site 0053)
New York, New York
Rochester Clinical Research, Inc. ( Site 0055)
Rochester, New York
Meridian Clinical Research, LLC ( Site 0032)
Vestal, New York
Carolina Institute for Clinical Research ( Site 0047)
Fayetteville, North Carolina
M3 Wake Research Associates ( Site 0040)
Raleigh, North Carolina
CTI Clinical Research Center ( Site 0071)
Cincinnati, Ohio
Velocity Clinical Research, Medford ( Site 0060)
Medford, Oregon
Hatboro Medical Associates / CCT Research ( Site 0065)
Hatboro, Pennsylvania
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.